___

• Messing EM. Urothelial tumors of the urinary tract. In Walsh PC, Retik AB, Vaughan ED, Wein AJ (eds), 8. baskı, WB Saunders Co, New York, 2002, cilt 4, s2732-2784.
• Quek ML, Sanderson K, Daneshmand S ve ark. New molecular markers for bladder cancer detection. Curr Opin Urol, 2004; 14: 259-264.
• Lotan Y, Roehrborn CG. Cost-effectiveness of a modified care protocol substituting bladder tumor markers for cystoscopy for the followup of patients with transitional cell carcinoma of the bladder: A decision analytical approach. J Urol, 2002; 167: 75-79.
• LokeshwarVB, Soloway MS. Current bladder tumor tests: Does their projected utility fulfill clinical necessity. J Uro1, 2001; 165: 1067-1077.
• Ramakumar S, Bhuiyan J, Besse JA ve ark. Comparison of screening methods in the detection of bladder caneer. J Uro1, 1999; 161: 388-389.
• Pode D, Shapiro A, Wald M ve ark. Noninvasive detection of bladder cancer with the BTA Stat test. J Uro1, 1999; 161: 443-446.
• Lokeshwar VB, Schroeder GL, Selzer MG ve ark. Bladder tumor markers for monitoring recurrence anf screening comparison of hyaluronic acid-- hyaluronidase and BTA-Stat tests. Cancer, 2000; 95: 61-72.
• Tsihlias J, Grossman HB. The utility of fıbrin/fıbrinogen degradation products in superficial bladder cancer. Urol Clin North Am, 2000; 27: 39-46.
• Thomas L, Leyh H, Marberger M ve ark. Multicenter trial of the quantitative BTA-TRAK assay in the detection of bladder cancer. Clin Chem, 1999; 45: 472-477.
• Grocela JA, McDougal WS. Utility of nuclear matrix protein (NMP22) in the detection of recurrent bladder cancer. Urol Clin North Am, 2000; 27: 47-51.
• Mian C, Lodde M, Haitel A ve ark. Comparison of two qualitative assays, the UBC-Rapid test and the BTA- Stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urology, 2000; 56: 228-231.
• Knudson W. Tumor associated hyaluronan: providing an extracellular matrix that facilitates invasion. Am J Pathol, 1996; 148: 1721-1726.
• LokeshwarVB, Obek C, Pham HT ve ark. Urinary hyaluronic acid and hyaluronidase: Markers for bladder cancer detection and evaluation of grade. J Uro1, 2000; 163: 348-356.
• LokeshwarVB, Young MJ, Goudarzi G ve ark. Identification of bladder tumor-derived hyaluronidase: Its similarity to HYAL1. Cancer Res, 1999; 59: 4464-4470.
• LokeshwarVB, Rubinowicz D, Schroeder GL ve ark. Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem, 2001, 276: 11922- 11932.
• Shariat SF, Casella R, Khoddami SM ve ark. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol, 2004; 171: 626-630.
• Ku JH, Kwak C, Lee HS ve ark. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol, 2004; 171: 631-635.
• Cheng L, Reiter RE, Jin Y ve ark.
• Immunocytochemical analysis of prostate stem cell antigen sa an adjunct marker for the detection of urothelial transitional cell carcinoma in voided urine specimens. J Urol, 2003; 169: 2094-2100.
• Shariat SF, Monoski MA, Andrews B ve ark. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urology, 2003; 61: 1053-1058.
• Shariat SF, Casella R, Monoski MA ve ark. The addition of urokinase-type plasminogen activator to urinary nuclear mstrix protein 22 and cytology improves the detection of bladder cancer. J Urol, 2003; 170: 2244-2247.
• Okegawa T, Kinjo M, Horie S ve ark. Detection of mucin 7 gene expression in exfoliated cells in the urine from patients with bladder tumor. Urology, 2003; 62: 182-186.
• Mian C, Pycha A, Wiener H ve ark. Immunocyt: a new tool for detecting transitional cell cancer of the urinary tract. J Urol, 1999; 161: 1486-1489.
• Erdem E, Dikmen G, Atsü N ve ark. Telomerase activity in diagnosis bladder cancer. Scand J Urol Nephrol, 2003; 37: 205-209.
• Melissourgos N, Kastrinakis NG, Davilas I ve ark. Detection of human telomerase reverse transcriptase mRNA in urine of patients with bladder cancer: evaluation of an emerging tumor marker. Urology, 2003; 62: 362-367.
• Glas AS, Roos D, Deutekom M ve ark. Tumor markers in the diagnosis primary bladder cancer: a systematic review. J Urol, 2003; 169: 1975-1982.
• Hoque MO, Lee CC, Cairns P ve ark. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nueleotide poly- morphism arrays and PCR-based microsatellite analysis. Cancer Res, 2003; 63: 2216-2222.
• Hoque MO, Lee J, Begum S ve ark. High-throughput molecular analysis of urine sediment for the detection of bladder cancer by high-density single nueleotide polymorphism array. Cancer Res, 2003; 63: 5723- 5726.
• Utting M, Werner W, Dahse R ve ark. Microsatellite analysis of free tumor DNA in urine, serum and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin Cancer Res, 2002; 8: 35-40.
• Duesberg P, Rausch C, Rasnick D ve ark. Genetic instability of caneer cells is proportional to their degree of aneuploidy. Proc Natl Acad Sci USA, 1998; 95: 13692.
• Jiang F, Caraway NP, Sabichi AL ve ark. Centresomal abnormality is common in and a potential biomarker for bladder cancer. Int J Cancer, 2003; 106: 661-665.
• Halling KC, King W, Sokolova IA ve ark. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol, 2000; 164: 1768-1775.
• Kelsey KT, Hirao T, Schned A ve ark. A population- based study of immunohistochemical detection of p53 alteration in bladder cancer. Br J Cancer, 2004; 90: 1572-1576.
• Cordon-Cardo C. p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol, 2004; 22:975-977.
• Puig P, Capodieci P, Drobnjak M ve ark. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is assoeiated with tumor progression in bladder cancer. Clin Cancer Res, 2003; 9: 5642-5651.
• Tuna B, Yörükoğlu K, Tüzel E, Güray M, Mungan U, Kırkalı Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract, 2003; 199: 323-328.
• Maas S, Warskulat U, Steinhoff C ve ark. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status. Urology, 2004; 63:392-397.
• Başakçı A, Kirkali Z, Tüzel E, Yörükoğlu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol, 2002; 41: 342-345.
• Bol MG, Baak JP, van Diermen B ve ark. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks. J Clin Pathol, 2003; 56: 447-452.
• Matsumoto K, Shariat SF, Casella R ve ark. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol, 2003; 170: 2246-2252.
• Kamai T, Tsujii T, Arai K ve ark. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res, 2003; 9: 2632-2641.
• Eijan AM, Sandes EO, Riveros MD ve ark. High expression of cathepsin B in transitional bladder carcinoma correlates with tumor invasion. Cancer, 2003; 98: 262-268.
• Kırkalı G, Tüzel E, Güler C, Gezer S, Kırkalı Z. Significance of Tissue laminin P1, elastase and fibronectin levels in transitional cell carcinoma of the bladder. Eur Urol, 2001; 39: 292-299.
• Sugimoto S, Maass N, Takimoto Y ve ark. Expression and regulation of tumor suppressor gene maspin in human bladder caneer. Cancer Lett, 2004; 203: 209-215.
• Kelloniemi E, Rintala E, Finne P ve ark. Tumor- associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology, 2003; 62: 249-253.
• Vasala K, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein as a prognostic marker in bladder cancer. Urology, 2003; 62: 952-957.
• Shariat SF, Matsumoto K, Kim J ve ark. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol, 2003; 170: 985-989.
• Slaton JW, Millikan R, Inoue K ve ark. Correlation ol metastasis related gene expression and relapse-free survival in patients with locally advaneed bladder cancer treated with cystectomy and chemotherapy. J Urol, 2004; 171: 570-574.
• Hoskin PJ, Sibtain A, Daley FM ve ark. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer, 2003; 89: 1290-1297.
• Duggan B, Williamson K. Molecular markers for predicting recurrence, progression and outcomes of bladder cancer (do the poster boys need new posters?). Curr Opin Urol, 2004; 14: 277-286.
• Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer, 2003; 89: 2172-2177.
• Celis JE, Celis P, Ostergaard M ve ark. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: a novel strategy for identifying metaplastic lesions. Cancer Res, 1999; 59: 3003-3009.
• Celis JE, Celis P, Palsdottir H ve ark. Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas. Mol Cell Proteomics, 2002; 1: 269-279.
• Ferguson RE, Selby PJ, Banks RE. Proteomic studies in urological malignancies. Contrib Nephrol, 2004; 141: 257-279.
• Ge H, Liu Z, Church GM ve ark. Correlation between transcriptome and interactome mapping data from Saccharomyces cerevisiae. Nat Genet, 2001; 29: 482- 486.
• Kırkalı Z, Tüzel E. Yüzeyel mesane tümörlerinde Av- rupa Kanser Araştırma ve Tedavi Derneği (EORTC) Deneyimi. Hemato-Onkoloji, 2004; 6: 47-50.
• Kırkalı Z, Tüzel E. Yüzeyel mesane kanserinde teda- vi. Hemato-Onkoloji 2004; 6: 42-46.
• Mungan MU, Canda AE, Tüzel E, Yörükoğlu K, Kır- kalı Z. Risk factors for mucosal prostatic involvement in superficial transitional cell carcinoma of the bladder. Eur Urol, 2005; 48:760-763.